24P the Predictive and Prognostic Role of Single Nucleotide Gene Variants in PD-1 and PD-L1 in Patients with Advanced Melanoma Treated with PD-1 Inhibitors

The introduction of immune-checkpoint inhibitors (ICIs) has revolutionized the treatment paradigm for advanced melanoma, leading to substantial benefit in overall survival (OS). However, several patients still do not benefit from ICIs and to date there are no predictive biomarkers for PD-1 inhibitors. PD-1 axis single nucleotide variants (SNVs) may affect receptor/ligand interactions in the tumor microenvironment and consequently the immune response and efficacy of ICIs. Based on this rationale, their predictive and prognostic role was investigated.